HCID Member | Biotech Specialty Pharma

InterveXion Therapeutics

4301 W. Markham St., #831
Little Rock, AR 72205 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Monoclonal Antibodies to Treat Substance Abuse.

Management R. Barry Holtz, Ph.D., President and Chief Executive Officer (CEO); S. Michael Owens, Ph.D., Chief Scientific Officer (CSO); W. Brooks Gentry, MD, Chief Medical Officer (CMO); Ralph Henry, Ph.D, Vice President of Biopharmaceutics; Gerald A. Damerow, Chief Financial Officer

Click here for Financial Data
Keywords: pharmaceutical, Immuno therapeutics, monoclonal antibody medications, drug addiction, vaccine, methamphetamine abuse, drug treatment, phencyclidine abuse, immunology, neurology

Comment


Updated: Mar. 31, 2011


Description

InterveXion is a pharmaceutical company using antibody-based therapies to treat human disease, beginning with substance abuse. Based in Little Rock, AR since 2004, we are a limited liability company w......view more

Products / Services

Our products are monoclonal antibody (mAb) medications that bind to toxic drugs in the blood stream and restrict transport into the brain, blocking the drug's rewarding effects and reducing damage to ......view more

Technology / Differentiation

InterveXion has developed drug-binding antibodies to treat some of the most addictive drugs in society. We have exclusively licensed critical patents and patent applications from UAMS and have the fi...view more

Market / Customers

In 2005, over 7,500 patients required emergency treatment for associated PCP use, and METH or AMP was involved in nearly 139,000 emergency department visits. In addition, over 150,000 sought treatment......view more


Competitors / Substitutes / Alternatives

InterveXion knows of no other groups with mAb therapies for METH or PCP. Many small molecule medications or combinations thereof have shown varying degrees of success, but have not shown broad-based s...view more

Strategy

The company strategy is to prove the safety and efficacy of our mAb medications through FDA-approved clinical trials. After successful pivotal efficacy trials, the company will be positioned for colla...view more

Revenue / Funding

InterveXion has received a STTR grant from the NIH National Institute on Drug Abuse which will total $3 million over five years. This funding will provide nearly the entire preclinical data set necess...view more

Status

Expected pre-IND meeting with the FDA during Spring 2009 to discuss PCP-mAb clinical safety trial. In final stages of selecting a candidate METH-mAb for clinical development. Over the last year, In...view more

Additional Information

UAMS BioVentures Business Incubator-UAMS BioVentures provides client companies significant development support....view more

RELATED COMPANIES